



FIGURE 1





6
4.6

Fig. 3a




FIG. 3b




FIG. 3C




FIG. 3d





FIG. 3e






FIG. 4




FIG. 5a




FIG. 5b




FIG. 5c




FIG. 5d




FIG. 5e

PATIENT CHARACTERISTICS	CLINICAL RESPONSE		
	Complete Response	Partial Response	Overall Response
Demographics			
Age			
Pathology			
Tumor Size			
Histology (1)			
Estrogen Receptor Status (2)			
Site of Metastasis			
Clinical Status			
Disease Stage (3)			
Menopausal Status (4)			
Prior Treatment Status			
Surgical (5)			
Chemotherapy (6)			
Radiotherapy			
Treatment Status			
Complications/Toxicity (7)			
Performance Status (8)			
Time to Progression/Treatment Failure			
(1) Infiltrating ductal, lobular (small-cell), medullary, tubular, squamous cell, adenocarcinoma, angiosarcoma			
(2) Positive or negative estrogen receptor			
(3) TNM staging criteria			
(4) Pre- or postmenopausal			
(5) Radical mastectomy, modified radical mastectomy, limited excision (lumpectomy)			
(6) CMF (cyclophosphamide, methotrexate, 5-fluorouracil), CA (cyclophosphamide and doxorubicin), tamoxifen			
(7) NCI common toxicity scale-Hematopoietic (leukopenia, neutropenia, anemia, thrombocytopenia), infectious (fever, localized infection, sepsis), neurological, endocrine (hyper- or hypoglycemia), cardiac (CHF), constitutional (nausea, vomiting, malnutrition, stomatitis, lethargy, malaise)			
(8) Karnofsky			

Fig. 6a

PATIENT CHARACTERISTICS	RESPONSE			
	Clinical	Complete Resource Use	Partial QOL	Overall QALYS
Demographics				
Age				
Pathology				
Tumor Size				
Histology (1)				
Estrogen Receptor Status (2)				
Site of Metastasis				
Risk/Prognostic Factors				
Familial				
Genetic Susceptibility				
APC				
AR				
AT				
BCL1				
BCL2				
BRCA1				
BRCA2				
CTSD				
EGF				
EGFR				
HRAS				
IGF1R				
LMYC				
NM23				
p53				
SRC				
Prior History				
In situ				
Invasive				
Atypical Hyperplasia				
Endogenous Endocrine Factors				
Age at Menarche				
Age at Menopause				
Age at First Pregnancy				
Exogenous Endocrine Factors				
Hormone Replacement Therapy				
Oral Contraceptives				
Environmental Factors				
Clinical Status				
Disease Stage (3)				
Menopausal Status (4)				
Prior Treatment Status				
Surgical (5)				
Chemotherapy (6)				
Radiotherapy				
Treatment Status				
Complications/Toxicity (7)				
Performance Status (8)				
Time to Progression/Treatment Failure				
Survival				
(1) Infiltrating ductal, lobular (small-cell), medullary, tubular, squamous cell, adenocarcinoma, angiosarcoma				
(2) Positive or negative estrogen receptor				
(3) TNM staging criteria				
(4) Pre- or postmenopausal				
(5) Radical mastectomy, modified radical mastectomy, limited excision (lumpectomy)				
(6) CMF (cyclophosphamide, methotrexate, 5-fluorouracil), CA (cyclophosphamide and doxorubicin), tamoxifen				
(7) NCI common toxicity scale-Hematopoietic (leukopenia, neutropenia, anemia, thrombocytopenia), infectious (fever, localized infection, sepsis), neurological, endocrine (hyper- or hypoglycemia) cardiac (CHF), constitutional (nausea, vomiting, malnutrition, stomatitis, lethargy, malaise)				
(8) Karnofsky				

Fig. 66

PATIENT CHARACTERISTICS	RESPONSE				Work Participation
	Clinical	Complete Resource Use	Partial QOL	Overall QALYS	
Demographics					
Age					
Pathology					
Tumor Size					
Histology					
<i>Infiltrating Ductal</i>					
<i>Lobular</i>					
<i>Medullary</i>					
<i>Tubular</i>					
<i>Squamous Cell</i>					
<i>Adenocarcinoma</i>					
<i>Angiosarcoma</i>					
<i>Other</i>					
Estrogen Receptor Status					
<i>Positive</i>					
<i>Negative</i>					
Site of Metastasis					
<i>Nodes</i>					
<i>Lung</i>					
<i>Bone</i>					
<i>Brain</i>					
<i>Liver</i>					
<i>Skin/Soft Tissue</i>					
<i>Adrenal</i>					
<i>Other</i>					
Clinical Status					
Disease Stage					
<i>Stage 0</i>					
<i>Stage I</i>					
<i>Stage IIA</i>					
<i>Stage IIB</i>					
<i>Stage IIIA</i>					
<i>Stage IIIB</i>					
<i>Stage IV</i>					
Menopausal Status					
<i>Premenopause</i>					
<i>Postmenopause</i>					
Prior Treatment Status					
<i>Surgical</i>					
Radical Mastectomy					
Modified Radical Mastectomy					
Limited Excision					
Other					
<i>Chemotherapy</i>					
CMF					
CA					
Tamoxifen					
Other					
<i>Radiotherapy</i>					
Treatment Status					
Complications/Toxicity					
<i>Hematopoietic</i>					
<i>Infectious</i>					
<i>Neurological</i>					
<i>Endocrine</i>					
<i>Cardiac</i>					
<i>Constitutional</i>					
Performance Status					
Time to Progression/Treatment Failure					
Survival					

Fig. 6c